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Abstract
Botulinum neurotoxins (BoNT/A-G), the most potent toxins known, act by cleaving three SNARE proteins required for
synaptic vesicle exocytosis. Previous studies on BoNTs have generally utilized the major SNARE homologues expressed in
brain (VAMP2, syntaxin 1, and SNAP-25). However, BoNTs target peripheral motor neurons and cause death by paralyzing
respiratory muscles such as the diaphragm. Here we report that VAMP1, but not VAMP2, is the SNARE homologue
predominantly expressed in adult rodent diaphragm motor nerve terminals and in differentiated human motor neurons. In
contrast to the highly conserved VAMP2, BoNT-resistant variations in VAMP1 are widespread across vertebrates. In
particular, we identified a polymorphism at position 48 of VAMP1 in rats, which renders VAMP1 either resistant (I48) or
sensitive (M48) to BoNT/D. Taking advantage of this finding, we showed that rat diaphragms with I48 in VAMP1 are
insensitive to BoNT/D compared to rat diaphragms with M48 in VAMP1. This unique intra-species comparison establishes
VAMP1 as a physiological toxin target in diaphragm motor nerve terminals, and demonstrates that the resistance of VAMP1
to BoNTs can underlie the insensitivity of a species to members of BoNTs. Consistently, human VAMP1 contains I48, which
may explain why humans are insensitive to BoNT/D. Finally, we report that residue 48 of VAMP1 varies frequently between
M and I across seventeen closely related primate species, suggesting a potential selective pressure from members of BoNTs
for resistance in vertebrates.
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Introduction
Botulinum neurotoxins (BoNTs) are a family of protein toxins
produced by diverse species of Clostridia, a genus of anaerobic
spore-forming bacteria [1,2]. These toxins paralyze humans and
animals by blocking neurotransmitter release primarily from
motor nerve terminals, causing death when respiratory muscles
are paralyzed. Adult humans and animals are usually exposed to
BoNTs by ingesting preformed toxins in food sources. The disease
caused by BoNTs is known as botulism, which has become rare in
humans due to improvements in food processing [3]. However,
botulism still accounts for large numbers of deaths in both wild
and domesticated animals, partly because the clostridia that
produce BoNTs are widespread in soils and water sediments [4].
There are seven major serotypes of BoNTs (types A-G) [1,2].
An eighth serotype (type H) has also been reported recently [5].
These toxins target and enter peripheral nerve terminals via
receptor-mediated endocytosis. Once inside neurons, BoNTs
translocate across endosomal membranes and act as proteases
cleaving one of three proteins essential for synaptic vesicle
exocytosis. Specifically, BoNT/B, D, F, and G cleave different
sites on the synaptic vesicle protein VAMP (also known as
synaptobrevin); BoNT/A, C, and E cleave different sites on the
peripheral membrane protein SNAP-25; and BoNT/C also
cleaves the plasma membrane protein syntaxin [1,2]. These three
proteins, known as SNARE proteins, form a complex that is the
core machinery mediating fusion of synaptic vesicle membranes to
plasma membranes [6].
For each of the three SNARE proteins, there are several
homologous genes in vertebrate genomes that encode closely
related proteins [6]. Previous studies of BoNTs mainly utilized
VAMP2, syntaxin 1, and SNAP-25. They are the predominant
forms expressed in brain and have been widely used as model
SNARE proteins. However, BoNTs cannot cross the blood-brain
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outbreaks. Rather, BoNTs act mainly on peripheral motor
neurons and cause death by paralyzing respiratory muscles such
as the diaphragm [7]. Therefore, the specific SNARE isoforms
expressed in diaphragm motor nerve terminals are the physiolog-
ical targets that determine the sensitivity of different animal species
to BoNTs. SNAP-25 and syntaxin 1 are expressed in motor nerve
terminals, and are likely the authentic physiological targets
[8,9,10]. However, recent data have raised doubts as to whether
VAMP2 is a physiologically relevant toxin target in diaphragm
motor neurons.
It has been reported that VAMP2 was not detected in rat sciatic
motor nerve terminals [11]. Instead, these nerve terminals express
VAMP1, another VAMP homologue [11]. It was also recently
reported that both VAMP1 and VAMP2 are co-expressed in
motor nerve terminals of triangularis sterni muscles in juvenile
mice [12]. Furthermore, the lack of VAMP1 expression in a
spontaneous VAMP1-null mutant mouse line results in a ,50%
reduction of synaptic transmission in the neuromuscular junctions
(NMJs) of juvenile mouse [12]. These VAMP1-null mice exhibit
severe motor dysfunction and usually die within 15 days after birth
[13]. These phenotypes suggest a possibility that VAMP2 is co-
expressed in motor neurons and can partially compensate for the
loss of VAMP1 during development, but VAMP1 gradually
becomes the dominant form that is essential for survival after 15
days. The expression of VAMP1 relative to VAMP2 in adult rat/
mouse diaphragm NMJs has not been examined, and the relative
contribution of VAMP1 versus VAMP2 at diaphragm NMJs in
adult animals remains unknown.
Interestingly, it has been shown that rat VAMP1 is resistant to
BoNT/B in vitro due to a single residue change (Q78V) from the
conserved VAMP1 sequence [14], whereas human VAMP1 is a
poor substrate for BoNT/D in vitro due to another residue change
(M48I) [15]. These in vitro data appear to correlate with the
toxicity data in vivo, as it has been a long-standing observation
that rats are insensitive to BoNT/B, with a median lethal dose
(LD50) that is ,10,000 times the value in mice [16]. Furthermore,
it has also been reported that synaptic transmission in isolated
human nerve-muscle biopsy tissues was not blocked by BoNT/D
[17]. In addition, there is no confirmed human botulism case
caused by BoNT/D, despite the prevalence of its association with
botulism in domesticated animals [3,18]. Finally, a recent study of
injecting low levels of BoNT/D into the extensor digitorum brevis
muscle (EDB) in human volunteers showed no significant paralysis,
indicating that humans are indeed insensitive to BoNT/D [19].
Despite these apparent correlations, it is not clear whether the
residue changes in VAMP1 underlie the resistance of a species to
BoNTs in vivo, and numerous potential confounding factors must
be considered when comparing the toxicity of BoNTs in different
species.
Here we demonstrate that VAMP1, but not VAMP2, is the
predominant form expressed at diaphragm NMJs in adult
mice/rats and in human motor neurons differentiated from
e m b r y o n i cs t e mc e l l s .F u r t h e r m o r e ,w ef o u n dt h a tr e s i d u e4 8
of VAMP1 is polymorphic between M and I in rats. Taking
advantage of this finding, we demonstrated that diaphragms
from rats homozygous for I48 are insensitive to BoNT/D as
compared to diaphragms from rats homozygous for M48. This
direct comparison within the same species demonstrates that
VAMP1 determines the sensitivity of a species to BoNT/D,
and indicates that I48 in human VAMP1 is likely the reason
for the insensitivity of humans to BoNT/D. Finally, we report
that residue 48 of VAMP1 varies between M and I across
seventeen closely related primate species, suggesting a poten-
tial selective pressure from BoNT/D.
Results
VAMP1, but not VAMP2, is expressed in diaphragm
motor nerve terminals in adult rats/mice and in human
motor neurons
Diaphragm motor nerve terminals are the physiological targets
that determine species susceptibility to BoNTs. We first examined
expression of VAMP1 versus VAMP2 at diaphragm tissues
dissected from adult rats and mice. These tissues were fixed,
permeabilized, and subjected to immunostaining assays to detect
VAMP1 or VAMP2 using their specific antibodies. The
diaphragm NMJs were labeled using a-bungarotoxin (a-BTX),
which binds to acetylcholine receptors opposing presynaptic motor
nerve terminals. We found that VAMP1 is expressed in nearly all
NMJs in both rat (Fig. 1A, upper panel) and mouse diaphragms
(Fig. S1A, upper panel). VAMP1 largely overlaps with a-BTX at
NMJs (Fig. 1A, S1A). In contrast, VAMP2 was not detected under
our assay conditions at NMJs in adult rat/mouse diaphragms
(Fig. 1A, lower panel; Fig. S1A, lower panel). The VAMP2
antibody utilized here has been widely used for both immuno-
staining and immunoblot analysis. We also confirmed that this
antibody can detect VAMP2 in mouse brain slices following the
same fixation and immunostaining protocol used for diaphragm
tissues (Fig. S1B).
We next assessed whether VAMP1 is also the dominant form in
human motor nerve terminals, utilizing cultured human motor
neurons differentiated from embryonic stem cells [20,21]. Primary
rat hippocampal neurons were also assayed as a control. As shown
in Fig. 1B, VAMP1 was detected in cell lysates of differentiated
human motor neurons, whereas VAMP2 was not detectable under
our assay conditions. In contrast, VAMP2 was readily detected in
cell lysates of rat hippocampal neurons, which do not express
appreciable levels of VAMP1. These results suggest that VAMP1
is likely the dominant form expressed in human motor neurons.
Author Summary
Botulinum neurotoxins (BoNTs) target peripheral motor
neurons and act by cleaving SNARE proteins, which are
essential for neurotransmitter release from nerve terminals.
SNARE proteins occur in multiple homologues and it has
been difficult to determine which one is the physiologi-
cally relevant toxin target in motor nerve terminals among
closely related SNARE homologues such as VAMP1 and
VAMP2. Here we report that, in contrast to the highly
conserved VAMP2, sequence variations in VAMP1 that
confer resistance to BoNTs are widespread across verte-
brates. In particular, residue 48 of VAMP1 is polymorphic
between BoNT/D-sensitive residue M and BoNT/D-resistant
residue I in rats. Taking advantage of this finding, we
carried out an intra-species comparison, which showed
that diaphragm motor nerve terminals from rats with I48 in
VAMP1 were insensitive to BoNT/D as compared to those
with M48. Since VAMP2 is conserved in rats, these data
demonstrate that VAMP1 is the physiologically relevant
toxin target in motor neurons. Interestingly, human
VAMP1 encodes the BoNT/D-resistant residue I48, which
may explain why humans are insensitive to BoNT/D.
Finally, we found that residue 48 of VAMP1 switches
frequently between M and I among 17 primate species,
suggesting a potential selective pressure from BoNT/D for
resistance in primates.
VAMP1 Is a Physiological Target of Botulinum Neurotoxins
PLOS Pathogens | www.plospathogens.org 2 July 2014 | Volume 10 | Issue 7 | e1004177Figure 1. VAMP1, but not VAMP2, is detected at diaphragm motor nerve terminals in adult rats and in human motor neurons. (A)
Diaphragms dissected from adult rats were subjected to immunostaining analysis to detect VAMP1 (upper panel) or VAMP2 (lower panel) at NMJs
using their specific antibodies. NMJs were labeled with a-BTX. The areas marked by white squares are enlarged to show the overlay between VAMP1
and a-BTX (upper panel), as well as the lack of VAMP2 at NMJs (lower panel). Scale bars represent 20 mm. (B) Cell lysates of human motor neurons
differentiated from embryonic stem cells, as well as cultured rat embryonic hippocampal neurons, were subjected to immunoblot analysis to detect
VAMP1 and VAMP2 using their specific antibodies. Actin served as a loading control.
doi:10.1371/journal.ppat.1004177.g001
Figure 2. Rat VAMP1 and rat diaphragm motor nerves are insensitive to BoNT/B. (A) The sequence alignment showing the BoNT/B
cleavage site within VAMP1 and VAMP2 in indicated species (r: rat; m: mouse; h: human). (B) VAMP1 was expressed in cultured rat hippocampal
neurons via lentiviral transduction. Neurons were exposed to the indicated concentrations of BoNT/B for 24 hrs. Cell lysates were collected and
subjected to immunoblot analysis to detect VAMP1 and VAMP2. (C) Immunoblot results of VAMP1/2 from panel B were quantified, normalized to
actin levels, and plotted to show VAMP1/2 levels after exposure to BoNT/B (N=3, error bars represent SEM). (D) The effect of BoNT/B on peak twitch
tension was determined in isolated mouse and rat phrenic nerve-hemidiaphragm preparations. Representative plots of peak twitch tension with time
after exposure to BoNT/B were normalized and compared between mice (red trace, 300 pM) and rats (black trace, 3 nM). (E) Time to attain 50%
paralysis (half-paralysis time, mean 6 SEM) in rat and mouse phrenic nerve-hemidiaphragm preparations after exposure to BoNT/B. Numbers in
parenthesis indicate the number of hemidiaphragms examined. ND: not determined.
doi:10.1371/journal.ppat.1004177.g002
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change at the toxin cleavage site
It has been a long-held observation that BoNT/B cannot cleave
rat VAMP1 in vitro, likely due to a single residue change at the
BoNT/B cleavage site (Fig. 2A) [14]. This differential sensitivity
between rat VAMP1 and VAMP2 toward BoNT/B provides an
opportunity to examine which VAMP homologue plays a
dominant role in diaphragm motor nerve terminals.
Because previous reports on the resistance of rat VAMP1 to
BoNT/B are based on in vitro studies using either cell lysates or
recombinant proteins, we first examined whether rat VAMP1 is
indeed resistant to BoNT/B in live neurons. To do so, we utilized
primary rat hippocampal neurons as a model. These neurons
express VAMP2, but not VAMP1 (Fig. 1B), thus serving as a
convenient VAMP1-null neuron model, which allows us to express
different versions of VAMP1 exogenously via lentiviral transduc-
tion. As shown in Fig. 2B, neurons expressing human (h-), mouse
(m-), or rat (r-) VAMP1 were incubated with a gradient of BoNT/
B. These neurons were subsequently harvested and subjected to
immunoblot analysis to detect cleavage of VAMP2 and VAMP1.
Cleavage of VAMP1 and VAMP2 resulted in the loss of their
immunoblot signals (Fig. 2B). The remaining VAMP immunoblot
signals were normalized to the signal of actin, and subsequently
plotted versus the BoNT/B concentrations (Fig. 2C). We found
that BoNT/B cleaved VAMP2, h-VAMP1, and m-VAMP1 with
similar efficiency, whereas r-VAMP1 was resistant to BoNT/B in
neurons (Fig. 2B, C).
We next determined whether the resistance of r-VAMP1 is due
to the Q78V residue change at the BoNT/B cleavage site (Fig. 2A).
This has been suggested to be the reason, but has not been
examined experimentally in neurons. We created a mutated r-
VAMP1 in which the V residue at the toxin cleavage site was
mutated to Q (Fig. 2A, B). This r-VAMP1 mutant was cleaved by
BoNT/B in neurons at a rate similar to m-VAMP1 (Fig. 2B, lower
panel), demonstrating that the Q to V change is indeed responsible
for the insensitivity of r-VAMP1 to BoNT/B in neurons.
Differential sensitivities of rat and mouse diaphragm
motor nerves to BoNT/B
We next examined whether the difference between rat and
mouse VAMP1 may lead to differential sensitivities of their
diaphragm motor neurons to BoNT/B. Here we utilized the well-
established phrenic nerve-hemidiaphragm preparation, in which
the phrenic nerve can be stimulated electrically to trigger muscle
contractions. Cleavage of VAMP in phrenic nerve terminals leads
to inhibition of synaptic vesicle exocytosis, which blocks muscle
contraction.
Using this assay, we found that incubation with 300 pM BoNT/
B caused a steep reduction of twitch tension in mouse diaphragm
muscles, culminating in nearly complete paralysis within 2 hours
(hrs) of toxin addition (Fig. 2D, red line). In contrast, twitch tension
in rat diaphragms exposed to a 10-fold higher concentration of
BoNT/B (3 nM, Fig. 2D, black line) showed no significant
reduction within 2 hrs. The slight reduction observed for rat
diaphragms is likely due to a natural run-down of the isolated
diaphragm tissues in the bath, since the same level of run-down
was observed in control rat diaphragms that were not exposed to
BoNT/B.
We further evaluated the sensitivity of rat versus mouse
diaphragms to BoNT/B by comparing the time required to
produce a 50% reduction of muscle twitch tensions (half-paralysis
time) under a series of BoNT/B concentrations. As listed in
Fig. 2E, 10 pM of BoNT/B caused a 50% reduction of muscle
twitch tension within 201.2639.1 min on mouse diaphragms. In
contrast, rat diaphragms exposed to 1000 pM and 3000 pM
concentrations of BoNT/B showed similar rates of reduction of
twitch tension as control diaphragms that were not exposed to
BoNT/B (,6 hrs, Fig. 2E), suggesting that rat diaphragm motor
nerves are essentially resistant to these levels of BoNT/B. Because
VAMP2 is conserved between rats and mice, the dramatically
different sensitivities between mouse and rat diaphragms to
BoNT/B are consistent with the hypothesis that VAMP1, rather
than VAMP2, is the physiologically relevant toxin target in
diaphragm motor nerve terminals in adult rats/mice.
Human VAMP1 is insensitive to BoNT/D due to a residue
change at position 48
It has been reported that human VAMP1 is insensitive to
BoNT/D in vitro, due to another single residue change at position
48 (M48I, Fig. 3A) [15]. Although position 48 is outside the
cleavage site for BoNT/D, it is within the motif where BoNT/D
binds and thus may affect the ability of BoNT/D to recognize and
bind VAMP1 efficiently [22].
We first evaluated whether human VAMP1 is indeed resistant
to BoNT/D in live neurons. As shown in Fig. 3B, primary rat
hippocampal neurons expressing human or mouse VAMP1 were
incubated with BoNT/D. Cleavage of VAMP1 and VAMP2 was
determined via immunoblot analysis of the neuron lysates. We
found that human VAMP1 was much less sensitive to BoNT/D
than mouse VAMP1 in neurons (Fig. 3B, C). Furthermore,
mutation of M48I in m-VAMP1 caused it to become insensitive to
BoNT/D, whereas mutation of I48M in h-VAMP1 allowed it to
be cleaved at a rate similar to wild type m-VAMP1 (Fig. 3B, C). In
contrast to BoNT/D, BoNT/F cleaved m-VAMP1, h-VAMP1,
and endogenous VAMP2 at similar rates (Fig. 3D, E), indicating
that I48 residue specifically reduces the cleavage efficacy of
BoNT/D. Together, these data confirmed that human VAMP1 is
insensitive to BoNT/D in neurons due to a residue change at
position 48.
Widespread residue changes in VAMP1 at BoNT cleavage
sites across vertebrates
We next evaluated whether toxin-resistant residue changes
occur in other species, by examining VAMP1 sequences available
in public databases. We found that the same residue change as in
rats (Q78V) also occurs in chickens and finches (Fig. S2). The
M48I residue change is even more widespread, including in
several primates, as well as in the rat, torpedo, wild boar,
Tasmanian devil, and elephant (Fig. S2).
In addition to these two sites, we also found residue changes in
VAMP1 at the cleavage sites for BoNT/F and BoNT/D (Q60E,
K61I, Fig. 3F, S2), in species such as the cat, dog, horse, and
panda. Introducing these two residue changes into m-VAMP1
renders it resistant to both BoNT/D and /F in neurons (Fig. 3F).
This mutant VAMP1 can still be cleaved by BoNT/B and tetanus
neurotoxin (TeNT), demonstrating the specificity of its resistance
to BoNT/D and /F (Fig. 3F). As shown in Fig. S2, additional
residue changes in VAMP1 also exist at the cleavage site for
BoNT/F5 (E57K). In contrast, VAMP2 from these species showed
no residue changes at the BoNT cleavage sites (Fig. S3).
Position 48 of VAMP1 is polymorphic between M and I
residues in rats
The finding that human VAMP1 is insensitive to BoNT/D is
consistent with previous observations that humans are less sensitive
to BoNT/D [19]. However, whether the former is the reason for
VAMP1 Is a Physiological Target of Botulinum Neurotoxins
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reported to also contain residue I at position 48 and is resistant to
BoNT/D in vitro [23,24], rats may serve as a model to investigate
whether VAMP1 with I48 can confer resistance to BoNT/D in
diaphragm motor nerve terminals. Surprisingly, our search of
public sequence databases revealed an additional rat VAMP1
sequence with residue M at position 48. Further analysis revealed
that residue M was reported from the genome sequence of Norway
rats, whereas residue I was reported for VAMP1 cloned from
Sprague Dawley (SD) rats (Fig. 4A), and this is the only difference in
VAMP1betweenthesetwotypesofrats. Therefore, residue48can be
either M or I among different rat species. The SD rat is a widely
utilized laboratory strain. As this is an outbred strain, we next
examined whether residue 48 could be polymorphic even within SD
rats. To answer this question, we sequenced VAMP1 from a total of
35 adult SD rats purchased from a commercial vendor (Charles
River). The results revealed that position 48 is the only polymorphic
residue, with 34% of SD rats homozygous with I residue and 28%
homozygous with M, while the rest were M/I heterozygous (Fig. 4A).
An intra-species comparison demonstrates that VAMP1
determines the sensitivity of rat diaphragm motor nerves
to BoNT/D
The finding that VAMP1 in the SD rat can have either M or I
at position 48 provides an ideal opportunity to address the
question of whether the M/I residue change in VAMP1 underlies
species sensitivity to BoNT/D. By comparing SD rats with
different genotypes in VAMP1, we can significantly reduce, if not
eliminate, any potential confounding factors that are always a
concern when comparing different species.
We thus examined the sensitivity of diaphragms from SD rats to
BoNT/D, using the phrenic nerve-hemidiaphragm tissue prepa-
ration described in Fig. 2D. These rats were ordered without
foreknowledge of their genotypes, subjected to our assay, and then
genotyped afterwards. Thus, the experimenter who measured the
sensitivity of each rat diaphragm to BoNT/D was blind to the
specific genotype of that rat. As the assay was done blindly, we
only compared the sensitivity of rat diaphragms to a fixed BoNT/
D concentration, 300 pM. As shown in Fig. 4B, rats that were
homozygous with residue M exhibited a half-paralysis time of
169621 min; whereas rats that were homozygous with residue I
had a half-paralysis time of 30768 min. The heterozygous rats
with M/I exhibited the same level of insensitivity as the
homozygous rats with residue I (with a half-paralysis time of
343637 min). These data demonstrate that M/I residues at
position 48 of VAMP1 largely determine the sensitivity of the
diaphragm motor nerve terminals to BoNT/D.
Frequent M/I switches at position 48 of VAMP1 among
different primate species
The diversity of primate species provides an ideal model for us
to further survey toxin-resistant residue changes in VAMP1
Figure 3. Human VAMP1 is a poor substrate for BoNT/D in neurons. (A) Sequence alignment showing a portion of VAMP1/2, which indicates
that human VAMP1 contains residue I at position 48, whereas mouse VAMP1 and VAMP2 both contain residue M at this position. The cleavage sites
for BoNT/F and BoNT/D are also designated by arrows. (B) VAMP1 was expressed in cultured rat hippocampal neurons via lentiviral transduction.
Neurons were exposed to the indicated concentrations of BoNT/D for 24 hrs. Cell lysates were collected and subjected to immunoblot analysis. Both
wild type h-VAMP1 and a mutant m-VAMP1 (M48I) were poorly cleaved by BoNT/D, whereas wild type m-VAMP1 and a mutant h-VAMP1 (I48M) were
efficiently cleaved by BoNT/D. (C) Immunoblot results from panel B were quantified and plotted (N=3, error bars represent SEM). (D) Experiments
were carried out as described in panel B, except that neurons were exposed to BoNT/F. Both m- and h-VAMP1 were cleaved by BoNT/F at similar
rates. (E) Quantification of immunoblot results from panel D (N=3, error bars represent SEM). (F) A mutant m-VAMP1 (VAMP1-mut) containing Q60E/
K61I was expressed in cultured rat hippocampal neurons via lentiviral transduction. Cells were exposed to the indicated toxins for 24 hrs, and cell
lysates were subjected to immunoblot analysis to detect cleavage of VAMP1. Cleavage of endogenous VAMP2 serves as an internal control to
demonstrate the activity of toxins. VAMP1 Q60E/K61I was resistant to both BoNT/F (1 nM) and BoNT/D (1 nM), but was readily cleaved by BoNT/B
(2 nM) and TeNT (0.15 nM).
doi:10.1371/journal.ppat.1004177.g003
VAMP1 Is a Physiological Target of Botulinum Neurotoxins
PLOS Pathogens | www.plospathogens.org 5 July 2014 | Volume 10 | Issue 7 | e1004177among closely related species. For this purpose, we selected
seventeen major primate species from four primate groups, which
represent ,87 million years (MYA) in primate evolution (Fig. 4C).
For several of the primates, VAMP1 sequences were available
from previous genomic studies. For the ones that were not
available, we sequenced the first four exons of their VAMP1 gene,
encoding residues 1–113.
All but 4 of these 113 amino acid positions in VAMP1 were
perfectly conserved across these seventeen primates. Two of the
variable amino acid positions, positions 7 and 106, differed in only
a single species (Fig. S4, P7L in Titi Monkey, and A106T in
Colobus). In contrast, the other two positions, residues 28 and 48,
changed multiple times among primates. Residue 28 varies among
three amino acids: M/L/T (Fig. S4), while residue 48 toggles
between M and I (Fig. 4C). As a control, we also analyzed VAMP2
sequences (residues 1–116) in nine major primate species (Fig. S5).
In contrast to VAMP1, VAMP2 is 100% conserved in all nine
primate species.
The functional significance of changes at residue 28 of VAMP1
is unknown, but it is unlikely to be related to BoNT sensitivity
since residue 28 is outside of both toxin recognition and cleavage
sites [22]. Residues at position 48, however, would determine the
susceptibility of a particular primate species to BoNT/D as we
demonstrated using the SD rat model (Fig. 4B). The distribution of
M/I at position 48 shows a tentative link to the geographic
distribution of primates. As shown in Fig. S6, all three primates
tested from the Americas encode the toxin-sensitive M residue,
whereas almost all African primates encode the toxin resistant I
residue. Primates sampled from Asia encode a mixture of the two.
Humans encode the toxin-resistant I, as do the majority of African
primates, which is in line with human emergence from the African
continent.
Discussion
VAMP1 and VAMP2 are two highly homologous synaptic
vesicle SNARE proteins. They exhibit largely distinct expression
patterns in the central and peripheral nervous systems, but also
overlap in many regions [11,25,26,27,28]. Both are substrates for
BoNT/B/D/F/G [1], but VAMP2 has been the prevalent
homologue utilized in the majority of studies on BoNT action.
This is partly because VAMP2 has been widely utilized as a model
VAMP protein. However, the specific VAMP isoform that is the
physiologically relevant toxin target in diaphragm motor nerve
terminals has not been established.
Here we examined the expression of VAMP1 versus VAMP2
using their specific antibodies, which showed that VAMP1 is the
predominant isoform expressed in diaphragm NMJs in adult
mice/rats. We further examined the role of VAMP1/VAMP2 in
diaphragms at functional levels. First, we confirmed that rat
diaphragms are insensitive to BoNT/B. This is consistent with a
dominant role for VAMP1 at diaphragms, since rat VAMP1 is
resistant to BoNT/B, whereas rat VAMP2 is readily cleaved by
BoNT/B. Second, we found that rats are polymorphic at residue
48 of VAMP1 between M that is sensitive to cleavage by BoNT/
D, and I that is a poor substrate for BoNT/D. Taking advantage
of this finding, we demonstrated that the sensitivity of rat
diaphragm motor nerves to BoNT/D correlates with the specific
residue 48 in VAMP1: diaphragms from rats with I48 were much
less sensitive to BoNT/D than diaphragms from rats with M48.
This unique intra-species comparison provides strong evidence
that VAMP1 is the dominant form in adult rat diaphragm motor
nerve terminals. This is likely also the case in humans, as we
showed that cultured human motor neurons differentiated from
embryonic stem cells mainly express VAMP1, but not VAMP2.
Figure 4. M/I48 residue changes exist across a broad range of primate species and determine the species sensitivity to BoNT/D. (A)
Norway rats contain M at position 48 of VAMP1, whereas VAMP1 amplified from a group of 35 SD rats revealed that 34% are homozygous with
residue I, 28% are homozygous with residue M, and the rest are I/M heterozygous at position 48 of VAMP1. (B) Muscle twitch tension was recorded
from rat phrenic nerve-hemidiaphragm preparations as described in Fig. 2D, except that muscles were exposed to BoNT/D (300 pM). Muscles were
dissected from adult SD rats without foreknowledge of their genotypes. Rat tissues were genotyped afterwards to determine the specific residue at
position 48 of VAMP1. The half-paralysis time was grouped based on the genotype of VAMP1 (I/I: 30767 min; I/M: 343637 min; M/M: 169621 min;
N=4; the error bars represent SEM). The difference between I and M groups was significant (P,0.0008, two tail t-test), whereas the difference
between I and I/M was not significant (P=0.38). (C) The residues at position 48 of VAMP1 in seventeen different primate species are indicated. These
primate species represent ,87 million years (MYA) of primate evolution, covering four major primate groups as indicated. The residue at position 48
is highly variable between different primate species and toggles frequently between M and I residues (highlighted in yellow).
doi:10.1371/journal.ppat.1004177.g004
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resistance of rat VAMP1 to BoNT/B is due to the presence of
residue V at position 78, whereas the resistance of human VAMP1
to BoNT/D is due to residue I at position 48. Interestingly, these
residue changes occur in multiple vertebrate species. In particular,
residue 48 is a hot spot that switches frequently between BoNT/D-
sensitive residue M and BoNT/D-insensitive residue I across
closely related primate species. Residue 48 is one of the key
residues within the highly conserved SNARE domain of VAMP1/
2, directly participating in the formation of the SNARE helix
bundle [29,30]. It is also a key position critical for endocytosis of
VAMP2 and its localization onto vesicles [31,32]. Because this M/
I switch occurs within closely related primate species, it is not likely
due to an evolutionary selection for any cellular functions.
Although we cannot exclude the possibility that the M/I switch
is a random and neutral event, the finding that this single change
determines the sensitivity of the species to BoNT/D suggests that
BoNT/D might have exerted a selective pressure on primates.
We were surprised to find that the M/I residue change also
occurs within the commonly utilized SD rats. It is a remarkable
example that a single residue polymorphism in animal models
exhibits a dramatic impact on their susceptibility to toxins/
pathogens. Consequently, it is essential to determine the specific
VAMP1 genotype of each SD rat when using this animal model
for studying BoNT/D action. Whether similar polymorphisms
exist in other species and humans remains to be resolved.
As low levels of BoNT/D selectively cleave human VAMP2,
but not VAMP1, it might be a unique toxin that can attenuate
synaptic transmission in VAMP2-expressing neurons in
humans, without the danger of causing muscle paralysis.
Therefore, it will be interesting to establish the distribution of
VAMP1 versus VAMP2 in neurons other than motor neurons,
such as sensory neurons involved in pain pathways. It has been
reported that both VAMP1 and VAMP2 are expressed in
trigeminal ganglion neurons involved in migraine [33].
V A M P 2i sa l s or e p o r t e dt ob ee x p r e s s e di nt h ed o r s a lh o r n
nerve terminals and in small- and medium-sized dorsal root
ganglion neurons [11]. The population of SD rats with I48
may provide a convenient model to explore the therapeutic
potential of using BoNT/D to target VAMP2-expressing cells.
Finally, our findings of frequent M/I changes among primate
species also provide crucial guidance for selecting appropriate
primate models for understanding the toxicity and therapeutic
effects of BoNT/D in humans.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
animal protocol was approved by the Standing Committee on
Animals of Harvard Medical School (Protocol Number: 04619).
For experiments carried out at the USAMRICD, the experimental
protocol was approved by the Animal Care and Use Committee at
the USAMRICD (Protocol Number: 109U949). All procedures
were conducted in accordance with the principles stated in the
Guide for the Care and Use of Laboratory Animals and the
Animal Welfare Act of 1966 (P.L. 89–544), as amended. All efforts
were made to minimize suffering of animals.
This study utilized a NIH-approved human embryonic stem cell
line (H9) for differentiation into human motor neurons, and it has
been approved by the Harvard Embryonic Stem Cell Research
Oversight (ESCRO) Committee (Protocol Number: E00030). The
identity of the donor of the embryo is anonymous and cannot be
readily ascertained by the investigator. It is therefore not
considered human subjects research and does not require IRB
review.
Antibodies, toxins, cDNAs and constructs
Mouse monoclonal antibodies for VAMP2 (69.1) were gener-
ously provided by E. Chapman (Madison, WI). The following
antibodies and reagents were purchased from the indicated
vendors: mouse monoclonal antibodies for actin (AC-15, Sigma-
Aldrich), rabbit polyclonal antibodies against synapsin (Millipore)
and VAMP1 (Synaptic Systems), Alexa-594 conjugated a-Bunga-
rotoxin (a-BTX, Invitrogen). BoNT/B (Okra), BoNT/D (D5995),
and BoNT/F (Langeland) were either purchased from Metabio-
logics (Madison, WI) or provided by E. Johnson (Madison, WI).
The cDNA encoding mouse VAMP1 was generously provided by
C. Hu (Louisville, KY). The cDNAs encoding human and rat
VAMP1 were purchased from Open Biosystems (Waltham, MA).
The full-length VAMP1 was sub-cloned into Lox-Syn-Syn
lentiviral vectors, which contain two separate neuronal specific
synapsin promoters, one drives expression of VAMP1, the other
drives expression of GFP as a marker. Mutagenesis studies were
carried out using the QuickChange Site-directed Mutagenesis kit
(Agilent Technologies).
Neuron culture and lentivirus preparations
Primary rat hippocampal neurons were prepared from E18-19
embryos using a papain dissociation kit (Worthington Biochem-
ical, NJ), as we described previously [34]. Lentiviruses were
prepared using packaging vectors VSV-G and D8.9 [34]. Viruses
were added to DIV 5 (days in vitro) neurons. Experiments were
carried out at DIV 14–16. This study was carried out in strict
accordance with the animal protocol approved by the Standing
Committee on Animals of Harvard Medical School (Protocol
Number: 04619). All procedures were conducted in accordance
with the principles stated in the Guide for the Care and Use of
Laboratory Animals and the Animal Welfare Act of 1966 (P.L. 89–
544), as amended.
Immunoblot analysis
Neurons were washed and lysed using RIPA buffer (50 mM
Tris, 1% NP40, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1%
SDS) with a protease inhibitor cocktail (Sigma-Aldrich). Cell
lysates were centrifuged for 10 min at 4uC. Supernatants were
subjected to western blot analysis using the enhanced chemilumi-
nescence (ECL) method (Pierce). The ECL signals were collected
using a Fuji LAS 3000 digital darkroom and quantified using
ImageJ software. The following antibody dilutions were used in
these assays: anti-VAMP1 (1:500); anti-VAMP2 (1:1000); anti-
actin (1:1000).
Nicking of BoNT/B
Since BoNT/B contains a mixed population of single chain
(inactive form) and di-chain (active form) toxins, it was
activated (nicked) by limited proteolysis to obtain a uniform
population of di-chain toxins. Briefly, BoNT/B (6.6 mM) was
diluted to 800 nM with 30 mM HEPES (pH 6.8) and
incubated at 37uC for 30 min with bovine pancreatic trypsin
type XI (13 mM). The reaction was stopped by addition of an
excess of soybean trypsin inhibitor (23 mM, type I-S) for
15 min. Bovine serum albumen (0.1%) was then added for
stability, and the nicked toxin was dispensed in single use vials
and stored at 220uCu n t i lu s e .
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Experiments were performed on isolated hemidiaphragm
muscles dissected from adult male Crl:CD1(ICR) mice (19–24 g)
and adult SD rats (250–400 g) (Charles River, Wilmington,
MA). Animals were euthanized by decapitation following
exposure to excess isoflurane. Hemidiaphragms with attached
phrenic nerves were mounted in 20-ml (mouse diaphragm) or
60-ml (rat diaphragm) tissue baths containing Tyrode’s solution
of the following composition (mM): NaCl, 137; KCl, 5; MgSO4,
1; NaHCO3, 24; NaH2PO4,1 ;C a C l 2,1 . 8 ,a n dg l u c o s e ,1 1 .T h e
solution was bubbled with a gas mixture of 95% O2/5% CO2
yielding a pH of 7.3–7.4. Resting tensions were maintained at
0.7 g (mouse diaphragm) or 2.0 g (rat diaphragm) to generate
optimal nerve-evoked contractions. This study was carried out
in strict accordance with the an i m a lp r o t o c o la p p r o v e db yt h e
Animal Care and Use Committeea tt h eU S A M R I C D( P r o t o c o l
Number: 109U949), and all procedures were conducted in
accordance with the principles stated in the Guide for the Care
and Use of Laboratory Animals and the Animal Welfare Act of
1966 (P.L. 89–544), as amended.
Human motor neuron differentiation
Human motor neurons were differentiated as previously
described [20,21]. Briefly, embryonic stem cells (hESCs, lines
H9, passages 19 to 35) were used to generate neuroectodermal
cells. Derived neuroectodermal cells were treated with retinoic
acid (0.1 mM) for caudalization in neural medium (NM:
DMEM/F12, nonessential amino acids, 2 mg/ml heparin, and
the neural cell supplement N2). The neuroepithelial clusters
were isolated and suspended in the NM in the presence of both
retinoic acid and purmorphamine (1 mM). The formed progen-
itor spheres were subsequently cultured on glass coverslips
coated with polyornithine and laminin (2–4 clusters/coverslip in
a 24-well plate) in the presence of 0.5 ml NM, supplemented
with BDNF (10 ng/ml; Peprotech), GDNF(10 ng/ml; R&D
Systems), IGF1 (10 ng/ml; Peprotech), cAMP (1 mM), ascorbic
acid (200 ng/ml, Innovative Cell Technology), and 50 nM
retinoic acid. It took 28 days to differentiate embryonic stem
cells into motor neurons. These neurons were further cultured
for 7 weeks to reach the stage that is considered to be mature for
motor neurons in culture. Thus, the age of human motor
neurons used in our experiments is 11 weeks old from the
original stem cells.
Sequencing VAMP1 from SD rats
Genomic DNA was extracted from rat tails. A 170 base pair
fragment that covers position 48 in the VAMP1 sequence was
amplified by PCR using the following primers: 59-
CCTGGCTTTCGATCTCT-39, and 59-TCAGCATCTT-
TATTCCTGC-39. The PCR fragments were then purified and
sequenced.
Immunostaining of diaphragm NMJs
Diaphragms were dissected from adult rats/mice (2-months-old)
and fixed overnight with 2% paraformaldehyde (PFA). Tissues
were incubated with a-BTX (1 mg/ml for 60 min) and then
permeabilized with 0.5% Triton X-100 for 30 min. Tissues were
further incubated with the blocking buffer (PBS with 3% BSA, 0.5
M NaCl and 0.3% Triton X-100) for 30 min, and then treated
with 0.2% citric acid for 30 min, washed with PBS, and incubated
with primary antibody diluted in blocking buffer (anti-VAMP1:
1:300; anti-VAMP2: 1:200) overnight at 4uC, rinsed and further
incubated with Alexa-488 conjugated secondary antibody for 2 hrs
at room temperature. Samples were washed and mounted. Images
were acquired using a confocal microscope (Leica SP5, 106
objective), and presented as maximum projections from Z-stack
acquisitions.
Immunostaining of brain slices
Wild type C57BL/6 mice were anesthetized with 2% avertin
(20 ml/g) and transcardially perfused with 4% PFA. The whole
brain was isolated and fixed in 4% PFA for 24 hrs, rinsed with
PBS, and immersed in 30% sucrose in PBS. Coronal brain
sections were cut at 30 mm segments with a freezing sliding
microtome. Brain slices were subjected to immunostaining
analysis with antibodies against VAMP2 (1:200) and synapsin
(1:400).
Muscle tension recording
Muscles were stimulated by application of supramaximal
volleys to the phrenic nerve via bipolar stainless steel electrodes
(6.0–9.0 V, 0.2 millisecond duration) at 0.033 Hz. Muscle
tensions were measured using Grass FT03 force displacement
transducers (Astro-Med, Inc., West Warwick, RI), digitized and
analyzed offline using pClamp software V10 (Molecular
Devices, Sunnyvale, CA). Tissues were maintained at 36uC
and exposed to BoNTs by adding toxins directly to the
incubation solution.
Sequencing primate VAMP1/VAMP2
Chimpanzee, gorilla, orangutan, white-cheeked gibbon, rhesus
macaque, marmoset, bushbaby and mouse lemur gene sequences
were obtained for both VAMP1 and VAMP2 from the UCSC
genome database (http://genome.ucsc.edu/). Vamp1 was se-
quenced from eight additional primate species from primate cell
lines as previously described [35]. The VAMP1 sequence was
amplified by PCR from cDNA using the primer pairs: 59-
CAGCCTCCGGAGAGGAAC-39 with 59-GCTTCATTTGAC-
TGCAAAGTCCC-39 or 59-TGTCTCGCCGCAGCCTC-39
with 59-GTAAATATGCCACATGCCTTTGGTGG-39. The
PCR fragments were then sequenced using the PCR primers
listed above or the following primers: 59-TTACAATAACTAC-
CACGATGATGGC-39 or 59-CCAGAGGAGAGTGGAGACC-
39. Primate VAMP1 gene sequences have been deposited in
GenBank (accession numbers KJ720564–KJ720571).
Supporting Information
Figure S1 VAMP2 expression can be detected in mouse
brain slices, but not in diaphragm motor nerve termi-
nals in adult mice. (A) Diaphragms dissected from adult mice
were subjected to immunostaining analysis to detect VAMP1
(upper panel) and VAMP2 (lower panel) at motor nerve
terminals using their specific antibodies. NMJs were labeled
with a-BTX. Scale bars represent 20 mm .( B )M i c ew e r ef i x e d
by perfusion with 4% PFA. Coronal brain slices were subjected
to immunostaining analysis with the same VAMP2 antibody as
used in panel A. Synapsin served as a marker for presynaptic
terminals. VAMP2 was detected in brain slices and was
largely co-localized with synapsin. The scale bar represents
10 mm.
(PDF)
Figure S2 Sequence alignment of VAMP1 in selected
vertebrate species. Selected vertebrates were organized based
on their phylogenetic relationship. Their VAMP1 residues at the
cleavage site for each BoNT (position 56/57 for BoNT/F5,
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position 83/84 for BoNT/G) were aligned, together with the
residue at position 48. Residues that differ from the conserved
sequence are highlighted in red.
(PDF)
Figure S3 Sequence alignment of VAMP2 in selected
vertebrate species. Sequence alignment of VAMP2 from
selected vertebrate species shows that VAMP2 is highly conserved,
with no residue changes at any site examined.
(PDF)
Figure S4 Sequence alignment of VAMP1 in selected
primate species. Protein sequences of exons 1–4 of the VAMP1
gene are aligned for the seven listed primate species. Out of the
113 amino acid positions shown, only four positions have
accumulated non-synonymous mutations. Positions 7 and 106
have a single non-synonymous mutation in only one primate
species (highlighted in green), whereas sites 28 and 48 are highly
variable, having mutated multiple times over primate evolution
(highlighted in yellow).
(PDF)
Figure S5 Sequence alignment of VAMP2 in selected
primate species. There are no non-synonymous mutations in
VAMP2 across nine major primate species examined here,
indicating that VAMP2 is highly conserved.
(PDF)
Figure S6 Geographic distribution of major primate
species. The geographic distribution of all seventeen primate
species examined in Fig. 4C was color-coded and plotted on the
map. The primates with M48 in VAMP1 are marked in blue,
whereas the primates with I48 in VAMP1 are marked in red.
(PDF)
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